

# Joohyuk Sohn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3498200/publications.pdf>

Version: 2024-02-01

141  
papers

12,617  
citations

93792

39  
h-index

30277

107  
g-index

143  
all docs

143  
docs citations

143  
times ranked

11505  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
2	Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). <i>Cancer Research</i> , 2022, 82, P2-12-13-P2-12-13.	0.4	0
3	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq1 1 0.784314ogBT /Ov	0.4	0
4	Abstract P1-17-09: Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P1-17-09-P1-17-09.	0.4	0
5	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). <i>Cancer Research</i> , 2022, 82, P1-16-01-P1-16-01.	0.4	0
6	Abstract P1-19-03: Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04). <i>Cancer Research</i> , 2022, 82, P1-19-03-P1-19-03.	0.4	0
7	Abstract PD6-07: Whole genome sequencing-based circulating tumor DNA profiling of metastatic breast cancer patients for molecular characterization and therapy response prediction. <i>Cancer Research</i> , 2022, 82, PD6-07-PD6-07.	0.4	0
8	Abstract P2-13-14: Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: Real-world evidence. <i>Cancer Research</i> , 2022, 82, P2-13-14-P2-13-14.	0.4	0
9	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2 <sup>+</sup> Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	3.2	90
10	Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09). <i>Cancer Research and Treatment</i> , 2022, , .	1.3	0
11	Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2405.	1.7	1
12	Eliceptant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor <sup>+</sup> Positive, Human Epidermal Growth Factor Receptor 2 <sup>-</sup> Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
13	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	13.9	854
14	Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1087-1087.	0.8	15
15	Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1017-1017.	0.8	5
16	Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 603-603.	0.8	1
17	Impacts of subtypes on clinical feature and outcome of male breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12528-e12528.	0.8	0
18	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor <sup>+</sup> positive (HR+), human epidermal growth factor receptor 2 <sup>-</sup> negative (HER2 <sup>-</sup> ) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1006-1006.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Phase 1b/2 study of GX-17 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.. Journal of Clinical Oncology, 2022, 40, 1081-1081.	0.8	3
20	A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).. Journal of Clinical Oncology, 2022, 40, 1098-1098.	0.8	1
21	Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS1108-TPS1108.	0.8	2
22	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTO trial.. Journal of Clinical Oncology, 2022, 40, 12084-12084.	0.8	0
23	Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).. Journal of Clinical Oncology, 2022, 40, 3025-3025.	0.8	7
24	Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2022, 40, 1100-1100.	0.8	6
25	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1118-TPS1118.	0.8	2
26	Risk of Lymphedema Following Contemporary Treatment for Breast Cancer. Annals of Surgery, 2021, 274, 170-178.	2.1	67
27	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 408-417.	3.2	21
28	Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2 <sup>-</sup> ) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Cancer Research, 2021, 81, PD2-04-PD2-04.	0.4	20
29	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. European Journal of Cancer, 2021, 144, 341-350.	1.3	5
30	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. Cancer Research and Treatment, 2021, 53, 1084-1095.	1.3	5
31	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Clinical and Translational Science, 2021, 14, 1015-1025.	1.5	2
32	Genomic landscape of extraordinary responses in metastatic breast cancer. Communications Biology, 2021, 4, 449.	2.0	3
33	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. International Journal of Cancer, 2021, 149, 917-924.	2.3	5
34	On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.. Journal of Clinical Oncology, 2021, 39, 1066-1066.	0.8	0
35	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2 <sup>-</sup> advanced breast cancer: MONARCH 2 & 3 trials. Cancer Science, 2021, 112, 2381-2392.	1.7	15
36	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113.	0.8	3

#	ARTICLE	IF	CITATIONS
37	acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).. Journal of Clinical Oncology, 2021, 39, TPS1100-TPS1100.	0.8	4
38	A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology, 2021, 32, 652-660.	0.6	56
39	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. British Journal of Cancer, 2021, 125, 679-686.	2.9	31
40	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 689587.	1.3	11
41	Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy. Scientific Reports, 2021, 11, 12105.	1.6	6
42	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2 <sup>-</sup> -Advanced Breast Cancer. Clinical Cancer Research, 2021, 27, 5801-5809.	3.2	3
43	Genomic Profiling of Premenopausal HR+ and HER2 <sup>-</sup> Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precision Oncology, 2021, 5, 1408-1420.	1.5	15
44	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 1275-1289.	5.1	118
45	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of Oncology, 2021, 32, 1571-1581.	0.6	225
46	338 <sup>th</sup> ...Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
47	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	1.4	4
48	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor <sup>+</sup> Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy <sup>+</sup> MONARCH 2. JAMA Oncology, 2020, 6, 116.	3.4	572
49	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor <sup>+</sup> Positive, HER2 <sup>-</sup> Negative Advanced Breast Cancer After Endocrine Therapy. Oncologist, 2020, 25, e243-e251.	1.9	45
50	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. Breast Care, 2020, 15, 408-414.	0.8	13
51	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Cancer Research and Treatment, 2020, 179, 687-697.	1.1	13
52	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 2020, 382, 610-621.	13.9	1,143
53	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 60-72.	5.1	161
54	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet, The, 2020, 396, 1090-1100.	6.3	625

#	ARTICLE	IF	CITATIONS
55	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 <sup>+</sup> , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
56	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 743-753.	1.1	4
57	Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 107-116.	1.1	2
58	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Annals of Oncology</i> , 2020, 31, 569-581.	0.6	253
59	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
60	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	3.2	27
61	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
62	A phase 1b study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1023-1023.	0.8	29
63	Ramosectron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Research and Treatment</i> , 2020, 52, 907-916.	1.3	12
64	Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase 1b/II study (KEYNOTE-899).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1072-1072.	0.8	3
65	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	1.1	3
66	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	5.1	86
67	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 <sup>+</sup> metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	2.9	9
68	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor <sup>+</sup> Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	3.4	62
69	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2 <sup>-</sup> negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5gBT /Over	3.7	5
70	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	13.9	656
71	Effect of primary tumor resection on overall survival in patients with stage IV breast cancer. <i>Breast Journal</i> , 2019, 25, 908-915.	0.4	6
72	Next generation sequencing and anti-cancer therapy. <i>Journal of the Korean Medical Association</i> , 2019, 62, 119.	0.1	4

#	ARTICLE	IF	CITATIONS
73	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 1669-1678.	2.3	14
74	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	1.9	9
75	Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. <i>Clinical Cancer Research</i> , 2019, 25, 2588-2600.	3.2	11
76	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. <i>International Journal of Cancer</i> , 2019, 145, 1179-1188.	2.3	199
77	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10). <i>TJ</i> 10.7848 14 rgBT4/Overl	1.3	4
78	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1013-1013.	0.8	26
79	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1008-LBA1008.	0.8	19
80	A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide. <i>Cancer Research and Treatment</i> , 2019, 51, 812-818.	1.3	4
81	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	1.3	5
82	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. <i>Clinical Breast Cancer</i> , 2018, 18, e1165-e1172.	1.1	1
83	Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective. <i>Clinical Breast Cancer</i> , 2018, 18, e167-e178.	1.1	30
84	The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. <i>Cancer Nursing</i> , 2018, 41, E49-E57.	0.7	0
85	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
86	CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator. <i>Oncotarget</i> , 2018, 9, 2622-2630.	0.8	13
87	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	1.3	10
88	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 904-915.	5.1	648
89	Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2018, 50, 801-812.	1.3	58
90	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 255-262.	1.1	3

#	ARTICLE	IF	CITATIONS
91	Chemotherapy-induced irreversible alopecia in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 527-533.	1.1	16
92	Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results. <i>Annals of Surgical Treatment and Research</i> , 2017, 92, 331.	0.4	19
93	Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea. <i>Journal of Breast Cancer</i> , 2017, 20, 228.	0.8	3
94	Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. <i>PLoS ONE</i> , 2017, 12, e0175048.	1.1	11
95	Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR. <i>Yonsei Medical Journal</i> , 2017, 58, 19.	0.9	19
96	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 <sup>-</sup> Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	0.8	1,105
97	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	0.8	1,099
98	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. <i>Journal of Clinical Oncology</i> , 2017, 35, 556-556.	0.8	60
99	PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS587-TPS587.	0.8	6
100	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	1.3	7
101	Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. <i>Journal of Breast Cancer</i> , 2016, 19, 76.	0.8	18
102	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0152585.	1.1	14
103	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1074-1074.	0.8	2
104	Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0149347.	1.1	16
105	Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. <i>Oncotarget</i> , 2016, 7, 24677-24687.	0.8	202
106	Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. <i>PLoS ONE</i> , 2015, 10, e0120320.	1.1	12
107	Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. <i>International Journal of Clinical Oncology</i> , 2015, 20, 878-890.	1.0	26
108	Prediction of short- and long-term survival for advanced cancer patients after ICU admission. <i>Supportive Care in Cancer</i> , 2015, 23, 1647-1655.	1.0	17

#	ARTICLE	IF	CITATIONS
109	Safety of eribulin in Korean patients with metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e12031-e12031.	0.8	3
110	The long term outcome of clinical trial-based treatment comparing standard treatment for metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, 11106-11106.	0.8	0
111	Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. Journal of Clinical Oncology, 2015, 33, e11579-e11579.	0.8	2
112	Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues. Korean Journal of Clinical Oncology, 2015, 11, 12-19.	0.1	1
113	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. Journal of Cancer, 2014, 5, 745-753.	1.2	46
114	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer, 2014, 120, 642-651.	2.0	107
115	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Supportive Care in Cancer, 2013, 21, 1751-1759.	1.0	38
116	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. BMC Cancer, 2013, 13, 583.	1.1	6
117	Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Breast, 2013, 22, 1205-1209.	0.9	5
118	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Investigational New Drugs, 2013, 31, 1300-1306.	1.2	23
119	Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Annals of Oncology, 2013, 24, 1485-1490.	0.6	31
120	Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. Neuro-Oncology, 2012, 14, 1105-1113.	0.6	22
121	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	6.3	1,165
122	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS ONE, 2012, 7, e45127.	1.1	15
123	Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab on A Chip, 2011, 11, 1118.	3.1	389
124	Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1123-1130.	1.2	29
125	Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials, 2011, 32, 2314-2326.	5.7	104
126	Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Cancer Chemotherapy and Pharmacology, 2010, 66, 425-431.	1.1	0



#	ARTICLE	IF	CITATIONS
127	Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. <i>Oncology</i> , 2010, 79, 324-330.	0.9	62
128	US Surveillance of Regional Lymph Node Recurrence after Breast Cancer Surgery. <i>Radiology</i> , 2009, 252, 673-681.	3.6	47
129	Sonographic Surveillance for the Detection of Contralateral Metachronous Breast Cancer in an Asian Population. <i>American Journal of Roentgenology</i> , 2009, 192, 221-228.	1.0	15
130	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2009, 91, 307-313.	1.4	103
131	Role of Sonography in the Detection of Contralateral Metachronous Breast Cancer in an Asian Population. <i>American Journal of Roentgenology</i> , 2008, 190, 476-480.	1.0	21
132	Multi-Disciplinary Treatment of a Rare Pelvic Cavity Ependymoma. <i>Yonsei Medical Journal</i> , 2007, 48, 719.	0.9	7
133	Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. <i>Cancer</i> , 2007, 109, 1829-1835.	2.0	40
134	Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. <i>Cancer</i> , 2007, 109, 1845-1950.	2.0	25
135	Retargeting of adenoviral gene delivery via Herceptin-PEG adenovirus conjugates to breast cancer cells. <i>Journal of Controlled Release</i> , 2007, 123, 164-171.	4.8	51
136	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 309-313.	1.1	11
137	Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. <i>Gene Therapy</i> , 2006, 13, 1010-1020.	2.3	94
138	Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin. <i>Human Gene Therapy</i> , 2006, 17, 379-390.	1.4	49
139	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 215-221.	1.1	63
140	Ad-mTERT-19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner. <i>Human Gene Therapy</i> , 2003, 14, 1415-1428.	1.4	111
141	dI-VSVG-LacZ, a Vesicular Stomatitis Virus Glycoprotein Epitope-Incorporated Adenovirus, Exhibits Marked Enhancement in Gene Transduction Efficiency. <i>Human Gene Therapy</i> , 2003, 14, 1643-1652.	1.4	17